Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, PK, and DDI Study of MRX-4 in Healthy Volunteers
NCT03033342Phase 1Completed
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of contezolid acefosamil in bacterial infection (6 arms), sponsored by MicuRx Pharmaceuticals. Primary endpoints: Safety of single and multiple ascending doses of MRX-4 at Day 14 and Summary of concentration time data for MRX-4 and its metabolites. Started Aug 2016; status: completed.
02
Drugs
contezolid acefosamil
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03033342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033342.